Peer support could boost HIV med adherence and curb substance use
NCT ID NCT05933226
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a program called Khanya, where trained peers (people with lived substance use experience) help HIV patients stick to their medication and reduce drug or alcohol use. The program is offered in steps: a basic version first, then a more intensive one if needed. Researchers will compare it to usual care over 12 months in South African primary care clinics. About 160 adults with HIV who have trouble taking their medication and have moderate-to-high substance use risk are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Khanya (peer-delivered behavioral intervention)
What this could lead to
If it works, this could provide a low-cost, scalable way to improve HIV medication adherence and reduce substance use in primary care settings.
What could go wrong
This is a relatively small trial (160 participants) testing a behavioral intervention, so results may not apply broadly. The intervention relies on peer counselors, which may vary in effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cape Town
Cape Town, Western Cape, South Africa